Navigation Links
Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
Date:3/26/2012

IRVINE, Calif., March 26, 2012 /PRNewswire/ -- Aviir, a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests and Guard A Heart, a non-profit foundation committed to raising awareness about heart disease prevention, will sponsor Storyland, a Red Carpet Charity Extravaganza in Hollywood on March 16th.

The party will have a whimsical Dr. Seuss theme, as homage to the children the charity gala benefits. A portion of the proceeds will go to the L.A. based non-profit "Reading, Writing, its Exciting," a program which helps at-risk children learn to read and write.

"It is our privilege to work in collaboration with Caus;ology to help further childhood literacy for those most vulnerable," said Dr. Harrington, CEO of Aviir Diagnostic Laboratories. "Through our support of this event we hope to raise awareness on the importance of heart disease prevention. As many as one in three kids and teens are overweight, contributing to early onset heart disease. Education is key for this highly controllable disease, and reading and writing is the foundation of any education. We are excited to be fostering literacy for children through this fun event."

The gala will be held at the world famous RISE building at Hollywood and Highland and will include a celebrity host, open bar, gourmet catering, DJ EQ, aerial dancers, photo booths, decadent desserts and event gift bags.

Tickets for this event can be purchased at: http://www.storyland.mobi/Storyland/After_Party_Tickets.html

About Aviir

Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools that improve cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.

About Guard A Heart

Guard A Heart is a non-profit foundation dedicated to raising awareness of heart disease prevention by spreading the word to guard your heart and save your life. Cardiovascular disease is the leading cause of death in the United States. If individuals know their risk and take the necessary steps, the good news is that most cardiovascular disease is preventable. Although heart disease is typically diagnosed in adulthood, its roots are often found in childhood. Compelling research has shown that plaque buildup in the arterial walls begins very early in life and progresses through increasing degrees of atherosclerosis. Intervention strategies and healthy lifestyle changes to reduce heart disease risk should begin in childhood when reversal of the process is easier, not later in life when the disease is more fully developed.  Guard a Heart Foundation provides funding for individuals who are unable to pay for cardiac risk assessments. Please visit www.guardaheart.org for more information.

For media inquiries, please contact:
Dina Scaglione
(949)910-9401
dina.scaglione@aviir.com


'/>"/>
SOURCE Aviir
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Berg Diagnostics Receives CLIA Certification and Launches Novel Vitamin D Assay
2. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
3. The butterfly effect in nanotech medical diagnostics
4. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
5. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
6. ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd.
7. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
8. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
9. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
10. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
11. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Md. , March 23, 2017  Northwest ... developing DCVax® personalized immune therapies for solid tumor ... the $7.5 million financing it announced last Friday, ... sold to several institutional investors securities totaling 28,843,692 ... per share, and 10,000,000 shares of Class C ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, president and CEO ... (CTC) as a 2017 Women of Innovation® finalist. Matloff will be among several ... , The dinner recognizes women accomplished in science, technology, engineering and math (STEM), ...
(Date:3/23/2017)... 2017  Agriculture technology company Cool Planet has closed ... conversion to commercialize its Cool Terra and Cool Fauna ... products that are simultaneously profitable as well as sustainable ... 18 months. This latest round of funding was led ... The company,s primary product, Cool Terra, can ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... human tissue regeneration from small lab samples to full-size tissues, bones, even whole ... establish a vascular system that delivers blood deep into the developing tissue. ...
Breaking Biology Technology:
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
(Date:3/9/2017)... FRANCISCO and MOUNTAIN VIEW, Calif. ... , "Eating Well Made Simple," and 23andMe , ... help guide better food choices.  Zipongo can now provide ... their food preferences, health goals and biometrics, but also ... certain food choices. Zipongo,s personalized food decision ...
(Date:3/2/2017)... NEW YORK , March 2, 2017 Summary ... to better understand Perrigo and its partnering interests and activities ... ... The Partnering Deals and Alliance since 2010 report provides an ... world,s leading life sciences companies. On demand company ...
Breaking Biology News(10 mins):